Jefferson University Hospitals

Physician Profile

Andrew Chapman, DO, FACP

Jefferson University Physician

Academic Title: Clinical Professor
Director, Division of Regional Cancer Care
Co-Director, Jefferson Senior Adult Oncology Center

Specialties
Geriatric Oncology
Hematology
Medical Oncology
Medical Oncology - Bladder Cancer
Medical Oncology - Breast Cancer
Medical Oncology - Colorectal Cancer
Medical Oncology - Esophageal Cancer
Medical Oncology - Gastrointestinal (GI) Cancer
Medical Oncology - Geriatric Oncology
Medical Oncology - Head & Neck Cancer
Medical Oncology - Hematologic Malignancies
Medical Oncology - Kidney Cancer
Medical Oncology - Leukemia/Lymphoma
Medical Oncology - Liver Cancer
Medical Oncology - Lung Cancer
Medical Oncology - Pancreatic Cancer
Medical Oncology - Prostate Cancer
Medical Oncology - Stomach Cancer

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
925 Chestnut Street
Suite 220A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 923-7390
Philadelphia
1300 Wolf Street
3rd Floor
Philadelphia PA 19148
Phone: (215) 334-5315
Fax: (215) 334-5305

Medical Services

Board Certifications

  • Medical Oncology
  • Hematology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Personal Statement

I feel that it is of utmost importance to develop a personalized treatment plan for every patient. This treatment plan should encompass the patient's goals in accord with the standards of care for the disease. Additionally, with a particular interest in Geriatric Oncology, I feel that age alone is never a criteria on which a treatment decision should be based.

Education

  • University of Health Sciences - College of Osteopathic Medicine, Medical School

Internship

  • Springfield Hospital

Residency

  • Penn Presbyterian Medical Center

Fellowship

  • Fox Chase Cancer Center

Recent Publications

Implementing a pharmacist-led, individualized medication assessment and planning (iMAP) intervention to reduce medication related problems among older adults with cancer

Patient-Centered Specialty Practice: Defining the Role of Specialists in Value-Based Health Care

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): An open-label, multicentre, randomised, phase 3 trial

Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study

Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer

Comorbidity in older adults with cancer

Geriatric assessment with management in cancer care: Current evidence and potential mechanisms for future research

Reply to M.-E. Rougé Bugat et al

A pharmacist-led medication assessment used to determine a more precise estimation of the prevalence of complementary and alternative medication (CAM) use among ambulatory senior adults with cancer

Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer

Predictors of chemotherapy dose reduction at first cycle in patients age 65years and older with solid tumors

Erratum: Silver oncologic tsunami: Quality issues in the senior adult oncology population (Journal of Oncology Practice (2015) 11, (190-192))

Silver oncologic tsunami: Quality issues in the senior adult oncology population

Development of a comprehensive multidisciplinary geriatric oncology center, the Thomas Jefferson university experience

Senior adult oncology: Three cases of advanced cancer in patients of advanced age

Metastatic unknown primary tumor presenting in pregnancy as multiple cerebral infarcts

Phase II: Trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy

Preliminary report on reduction of esophagitis by amifostine in patients with non-small-cell lung cancer treated with chemoradiotherapy

Increase of βIII- and βIVa-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance

Phase I study of paclitaxel and estramustine: Preliminary activity in hormone-refractory prostate cancer